Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 3 3Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 9INDUSTRY 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 1

Conditions

Multiple Myeloma 5Recurrence 1Hematologic Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × talquetamab × Clear all
NCT04634552 2026-06-05

MonumenTAL-1

Janssen Research & Development, LLC

Phase 2 Recruiting
510 enrolled 1 FDA
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT06500884 2026-06-05

Talisman

Janssen Research & Development, LLC

Phase 2 Recruiting
210 enrolled
Plasma cell

Multiple Myeloma

NCT06550895 2026-06-05

MonumenTAL-8

Janssen Research & Development, LLC

Phase 2 Active not recruiting
11 enrolled
Plasma cell

Multiple Myeloma

NCT06577025 2026-06-05

aMMbition

Janssen Research & Development, LLC

Phase 2 Active not recruiting
43 enrolled
Plasma cell

Multiple Myeloma

NCT03601078 2026-03-04

KarMMa-2

Celgene

Phase 2 Completed
312 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡